Morgan Stanley’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-687,107
| Closed | -$14.7M | – | 8458 |
|
|
2026
Q1 | $14.7M | Sell |
687,107
-863,167
| -56% | -$12.2M | ﹤0.01% | 3230 |
|
|
2025
Q4 | $14.4M | Buy |
1,550,274
+246,245
| +19% | +$2.06M | ﹤0.01% | 3244 |
|
|
2025
Q3 | $9.19M | Sell |
1,304,029
-49,119
| -4% | -$338K | ﹤0.01% | 3620 |
|
|
2025
Q2 | $8.8M | Buy |
1,353,148
+643,733
| +91% | +$4.43M | ﹤0.01% | 3554 |
|
|
2025
Q1 | $5.63M | Sell |
709,415
-370,853
| -34% | -$4M | ﹤0.01% | 3834 |
|
|
2024
Q4 | $13.7M | Buy |
1,080,268
+305,757
| +39% | +$4.25M | ﹤0.01% | 3110 |
|
|
2024
Q3 | $10.8M | Buy |
774,511
+607,265
| +363% | +$8.66M | ﹤0.01% | 3366 |
|
|
2024
Q2 | $2.3M | Sell |
167,246
-65,304
| -28% | -$955K | ﹤0.01% | 4468 |
|
|
2024
Q1 | $3.84M | Sell |
232,550
-101,889
| -30% | -$1.52M | ﹤0.01% | 4123 |
|
|
2023
Q4 | $4.88M | Buy |
334,439
+175,993
| +111% | +$2.13M | ﹤0.01% | 3935 |
|
|
2023
Q3 | $1.94M | Sell |
158,446
-79,258
| -33% | -$1.03M | ﹤0.01% | 4413 |
|
|
2023
Q2 | $2.84M | Buy |
237,704
+53,785
| +29% | +$702K | ﹤0.01% | 4190 |
|
|
2023
Q1 | $2.46M | Buy |
183,919
+96,654
| +111% | +$1.89M | ﹤0.01% | 4322 |
|
|
2022
Q4 | $1.88M | Sell |
87,265
-20,140
| -19% | -$413K | ﹤0.01% | 4509 |
|
|
2022
Q3 | $2.15M | Buy |
107,405
+70,365
| +190% | +$1.5M | ﹤0.01% | 4376 |
|
|
2022
Q2 | $662K | Buy |
37,040
+20,587
| +125% | +$213K | ﹤0.01% | 5269 |
|
|
2022
Q1 | $162K | Buy |
16,453
+2,489
| +18% | +$32.9K | ﹤0.01% | 6034 |
|
|
2021
Q4 | $236K | Buy |
13,964
+10,997
| +371% | +$226K | ﹤0.01% | 5980 |
|
|
2021
Q3 | $70K | Buy |
2,967
+593
| +25% | +$14.2K | ﹤0.01% | 6560 |
|
|
2021
Q2 | $54K | Buy |
+2,374
| New | +$49.5K | ﹤0.01% | 6637 |
|
Other funds holding DAWN
Morgan Stanley's DAWN Position: Q2 2026 in Review
Morgan Stanley sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 687,107 shares — an estimated $14.7M sold.
Morgan Stanley first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $14.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Morgan Stanley reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 687,107 Day One Biopharmaceuticals shares in Q2 2026, an estimated $14.7M.
- Morgan Stanley first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- Morgan Stanley's Day One Biopharmaceuticals position peaked at $14.7M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.